Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $173.25.

Several analysts have commented on ASND shares. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Monday, December 25th. Wedbush boosted their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Jefferies Financial Group assumed coverage on Ascendis Pharma A/S in a research report on Wednesday, December 20th. They set a “buy” rating and a $150.00 target price on the stock. Citigroup boosted their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a research report on Thursday, February 8th. Finally, Wells Fargo & Company boosted their target price on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently modified their holdings of the company. US Bancorp DE grew its holdings in shares of Ascendis Pharma A/S by 35.2% in the 4th quarter. US Bancorp DE now owns 284 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 74 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 91 shares during the period. GAMMA Investing LLC grew its holdings in shares of Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 102 shares during the period. Envestnet Asset Management Inc. lifted its stake in Ascendis Pharma A/S by 3.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 3,226 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 105 shares in the last quarter. Finally, Guggenheim Capital LLC lifted its stake in Ascendis Pharma A/S by 7.2% in the 1st quarter. Guggenheim Capital LLC now owns 2,008 shares of the biotechnology company’s stock valued at $236,000 after buying an additional 135 shares in the last quarter.

Ascendis Pharma A/S Stock Down 0.6 %

ASND opened at $145.23 on Tuesday. The business has a 50 day moving average price of $149.10 and a two-hundred day moving average price of $123.28. The company has a market cap of $8.46 billion, a PE ratio of -15.70 and a beta of 0.50. Ascendis Pharma A/S has a 52 week low of $66.03 and a 52 week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, beating the consensus estimate of ($2.15) by $0.49. The firm had revenue of $148.62 million during the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.18 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.